Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Year: 2020
Type: article
Study design: Observational Study
Abstract: Purpose: We evaluated the predictive value of pretreatment ctDNA to inform therapeutic outcomes in patients with metastatic melanoma relative to type and line of treatment. Experimental Design: Plasma circulating tumor DNA (ctDNA) was quantified in 125 samples collected from 110 patients prior to commencing treatment with immune checkpoint inhibitors (ICIs), as first- (n = 32) or second-line (n = 27) regimens, or prior to commencing first-line BRAF/MEK inhibitor therapy (n = 66). An external validation cohort included 128 patients commencing ICI therapies in the first- (N = 77) or second-line (N = 51) settings. Results: In the discovery cohort, low ctDNA (≤20 copies/mL) prior to commencing therapy predicted longer progression-free survival (PFS) in patients treated with first-line ICIs [HR, 0.20; 95% confidence interval (CI) 0.07–0.53; P < 0.0001], but not in the second-line setting. An independent cohort validated that ctDNA is predictive of PFS in the first-line setting (HR, 0.42; 95% CI, 0.22–0.83; P = 0.006), but not in the second-line ICI setting. Moreover, ctDNA prior to commencing ICI treatment was not predictive of PFS for patients pretreated with BRAF/MEK inhibitors in either the discovery or validation cohorts. Reduced PFS and overall survival were observed in patients with high ctDNA receiving anti–PD-1 monotherapy, relative to those treated with combination anti–CTLA-4/anti–PD-1 inhibitors. Conclusions: Pretreatment ctDNA is a reliable indicator of patient outcome in the first-line ICI treatment setting, but not in the second-line ICI setting, especially in patients pretreated with BRAF/MEK inhibitors. Preliminary evidence indicated that treatment-naïve patients with high ctDNA may preferentially benefit from combined ICIs.
Source: Clinical Cancer Research
Authors: Gabriela Marsavela, Jenny Lee, Leslie Calapre, Stephen Q. Wong, Michelle R. Pereira, Ashleigh C. McEvoy, Anna L. Reid, Cleo Robinson, Lydia Warburton, Afaf Abed, Muhammad A. Khattak, Tarek M. Meniawy, Sarah-Jane Dawson, Shahneen Sandhu, Matteo S. Carlino, Alexander M. Menzies, Richard A. Scolyer, Georgina V. Long, Benhur Amanuel, Michael Millward, Melanie R. Ziman, Helen Rizos, Elin S. Gray
Institutions: Edith Cowan University, The University of Sydney, Chris O’Brien Lifehouse, Melanoma Institute Australia, Macquarie University, The University of Melbourne, Peter MacCallum Cancer Centre, The University of Western Australia, Queen Elizabeth II Medical Centre, Pathwest Laboratory Medicine, Sir Charles Gairdner Hospital, Fiona Stanley Hospital, Fiona Stanley Fremantle Hospitals Group, Westmead Hospital, Royal North Shore Hospital, Royal Prince Alfred Hospital, NSW Health Pathology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Circulating tumour DNA as a noninvasive biomarker in melanoma, G1863204419, Acquired resistance to PD1 inhibition in melanoma, Oncogenic Signaling and Cancer Therapy, Liquid Biopsy for Personalised Monitoring of Melanoma Patients, Development of systemic therapies to improve response and prevent resistance in the treatment of Melanoma
OpenAlex ID: W3093226754
